Caraway Therapeutics, Inc. Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

Caraway Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on small molecules that activate cellular clearance by enhancing lysosomal function. Its approach combines genetic insights with an understanding of cellular recycling to accelerate the removal of toxic materials and defective components. The company targets neurodegenerative and rare diseases associated with impaired lysosomal activity, including Parkinson’s disease, ALS, and lysosomal storage diseases.

Caraway operates in the biotechnology research sector and seeks to translate lysosomal biology into disease-modifying therapies. In 2023, it announced a collaboration with AbbVie to develop and commercialize TMEM175 activators, a lysosomal ion channel related to Parkinson's disease.

Sign up for free to view info

Company overview Employee directory